New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture

Current Opinion in Cardiology

Volumn 26, Issue 6, 2011, Pages 569-575

  Martin, Kenneth ^a   O'Sullivan, John F ^a   Caplice, Noel M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

atherosclerosis; endothelial cells; microRNA; monocytes; smooth muscle cells

Indexed keywords

MICRORNA;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HUMAN; MACROPHAGE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER;

ARTERIOSCLEROSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; MICRORNAS; MONOCYTES; MUSCLE, SMOOTH; RUPTURE;

EID: 80054712637     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834b7f95     Document Type: Review

References (66)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
3. Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008;117:2458-2466. (Pubitemid 351670452)
4. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588. (Pubitemid 44209181)
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
6. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006;11:441-450. (Pubitemid 44430905)
7. Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010;285:21496-21507.
8. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677-684. The evaluation of circulating miRs as potential disease biomarkers.
9. Ponomarev ED, Veremeyko T, Barteneva N, et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011;17:64-70.
10. Lu C, Huang X, Zhang X, et al. MiR-221 and miR-155 regulate human dendritic cell development, apoptosis and IL-1 2 production through targeting of p27kip1, KPC1 and SOCS-1. Blood 2011;117:4293-4303.
11. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-12486. (Pubitemid 44267285)
12. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-1573. An elegant study identifying miR-33 as a crucial regulator of cellular cholesterol status.
13. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705-710. Definitive article on the alteration of SMC phenotype by miR-143 and miR-145.
14. Lin Y, Liu X, Cheng Y, et al. Involvement of microRNAs in hydrogen peroxidemediated gene regulation and cellular injury response in vascular smooth muscle cells. J Biol Chem 2009;284:7903-7913.
15. Liu X, Cheng Y, Zhang S, et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009;104:476-487.
16. Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108:3068-3071.
17. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009;324:1710-1713.
18. Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009;284:35134-35143.
19. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-1 26 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008;105:1516-1521. (Pubitemid 351346546)
20. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116.
21. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010;7:77-86. The definitive review on monocyte subsets and their participation in atherosclerosis.
22. Ikejima H, Imanishi T, Tsujioka H, et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010;74:337-345.
23. Shalhoub J, Cross AJ, Davies AH, Monaco C, editors. Multi-analyte profiling in human carotid atherosclerosis uncovers signatures of interferon-gamma priming and classical macrophage polarization in unstable plaques. Chicago: Arterioscler Thromb Vasc Biol Scientific Sessions; 2011.
24. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1424-1432.
25. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990;87:4828-4832.
26. Irvine KM, Andrews MR, Fernandez-Rojo MA, et al. Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. J Leukoc Biol 2009;85:278-288.
27. Yeamans C, Wang D, Paz-Priel I, et al. C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood 2007;110:3136-3142. (Pubitemid 350106304)
28. Zhang X, Jin J, Tang Y, et al. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 2009;182:3928-3936.
29. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008;58:1001-1009. (Pubitemid 351564001)
30. Nakasa T, Shibuya H, Nagata Y, et al. The inhibitory effect of microRNA-1 46 expression on bone destruction in arthritis. Arthritis Rheum 2011;58:1284-1292.
31. Chen T, Li Z, Jing T, et al. MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells. FEBS Lett 2011;585:567-573.
32. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399. (Pubitemid 27329409)
33. Clarke M, Bennett M. Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 2006;5:2329-2331. (Pubitemid 44785840)
34. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986;314:488-500.
35. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503. (Pubitemid 24379627)
36. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996;347:305-307. (Pubitemid 26041046)
37. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801. (Pubitemid 38823766)
38. O'Sullivan JF, Martin K, Caplice NM. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis 'a finger in the dam'. J Am Coll Cardiol 2011;57:383-389. For further reading on the potential of miRs to modify plaque stability and in-stent restenosis.
39. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009;119:2634-2647.
40. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009;16:1590-1598.
41. Dai G, Kaazempur-Mofrad MR, Natarajan S, et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and-resistant regions of human vasculature. Proc Natl Acad Sci USA 2004;101:14871-14876. (Pubitemid 39410767)
42. Haver VG, Slart RH, Zeebregts CJ, et al. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? Trends Cardiovasc Med 2010;20:65-71.
43. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007;49:2073-2080. (Pubitemid 46771052)
44. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-2038. (Pubitemid 39331918)
45. Moulton KS. Plaque angiogenesis: its functions and regulation. Cold Spring Harb Symp Quant Biol 2002;67:471-482. (Pubitemid 36775543)
46. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008;29:12-15.
47. Wang S, Olson EN. AngiomiRs: key regulators of angiogenesis. Curr Opin Genet Dev 2009;19:205-211.
48. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-271.
49. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
50. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817.
51. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011. [Epub ahead of print]
52. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-1070. The key study on the therapeutic delivery of RNA interference.
53. Lennox KA, Behlke MA. A direct comparison of antimicroRNA oligonucleotide potency. Pharm Res 2010;27:1788-1799.
54. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294-2304. (Pubitemid 43985667)
55. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
56. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006;372:137-141.
57. Grimm D, Wang L, Lee JS, et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest 2010;120:3106-3119.
58. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070. (Pubitemid 41161233)
59. Michael MZ, O'Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-891. (Pubitemid 37288707)
60. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009;106:3207-3212.
61. Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion in nonsmall cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008;373:607-612.
62. Hurst DR, Edmonds MD, Scott GK, et al. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-1283.
63. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005;102:19075-19080. (Pubitemid 43049568)
64. Du ZM, Hu LF, Wang HY, et al. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One 2011;6:e19137.
65. Hunt S, Jones AV, Hinsley EE, et al. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett 2011;585:187-192.
66. Furuta M, Kozaki KI, Tanaka S, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31:766-776.